Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Unigene Laboratories Stories

2012-02-27 08:01:00

BOONTON, N.J., Feb. 27, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced the Company's Vice President of Research and Development, Nozer Mehta, Ph.D., will be presenting at IBC's 4th Annual AsiaTIDES Oligonucleotide and Peptide® Conference being held at the Sheraton Miyako Hotel in Tokyo, Japan. The TIDES Oligonucleotide and Peptide Conferences are the premier forums...

2012-02-08 08:51:00

BOONTON, N.J., Feb. 8, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), today announced the expansion of its Biotechnologies strategic business unit (SBU) with the promotion of Gregory T. Mayes, Esq. to the position of Chief Business Officer and the appointment of Jane Pepper, M.B.A, Ph.D. to Senior Director, Business Development. Mr. Mayes' promotion to Chief Business Officer extends a successful tenure at Unigene since his appointment to Vice President, Corporate...

2012-02-07 07:33:00

BOONTON, N.J., Feb. 7, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced that Ashleigh Palmer, President and Chief Executive Officer will be presenting a corporate overview at the 14th Annual BIO CEO & Investor Conference in New York, NY. Mr. Palmer's presentation is scheduled to begin at 11:00 a.m. ET on Monday, February 13, 2012. Individuals can listen to a...

2012-02-01 08:51:00

BOONTON, N.J., Feb. 1, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) today announced that it has received the 2012 Drug Delivery Partnerships(TM) ("DDP") Innovation Award in the Industry Achievement category in recognition of the Company's 2011 clinical advances in the oral delivery of peptides. This year's DDP Award recipients were voted on and selected by conference attendees, including leading scientists, pharmaceutical executives and drug delivery key...

2012-01-11 07:31:00

BOONTON, N.J., Jan. 11, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that it had been granted U.S. Patent No. 8,076,291 from the United States Patent and Trademark Office (USPTO). The patent, which was issued on December 13, 2011, provides intellectual property (IP) protection for peptides and pharmaceutical compositions containing such peptides for the suppression...

2012-01-09 07:31:00

BOONTON, N.J., Jan. 9, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) today provided a business outlook for 2012 and highlighted multiple near-term catalysts that have the potential to monetize assets and unlock significant value over the next 12 months. Management believes the key elements are in place to address the Company's debt and begin restructuring the balance sheet in 2012. Unigene's CEO, Senior Management and Board of Directors signaled confidence and...

2012-01-04 07:01:00

BOONTON, N.J., Jan. 4, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced that Ashleigh Palmer, President and Chief Executive Officer, will present a corporate overview at the Biotech Showcase(TM) 2012 in San Francisco, CA on Monday, January 9, 2012 at 11:30 a.m. PT (2:30 p.m. ET). Mr. Palmer's presentation will include an overview of Unigene's industry-leading oral peptide...

2011-12-19 07:31:00

BOONTON, N.J., Dec. 19, 2011 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) today highlighted its significant accomplishments in 2011 and announced that its management team has put key elements in place to begin addressing the capital structure and eliminating the inherited debt. Unigene also reaffirmed that the Company's projected cash flow is expected to fund operations into the second half of 2012, following a corporate reorganization to better strategically align...

2011-12-13 07:00:00

PHILADELPHIA, Dec. 13, 2011 /PRNewswire/ -- Tarsa Therapeutics today confirmed that it is planning to submit a New Drug Application (NDA) to the Food and Drug Administration (FDA) in the second half of 2012 for OSTORA(TM), the company's oral recombinant salmon calcitonin tablet for the treatment of postmenopausal osteoporosis. This follows a formal pre-NDA dialogue with the FDA that verified the results from Tarsa's Phase III ORACAL trial and the requirements for regulatory approval,...

2011-12-07 07:02:00

BOONTON, N.J., Dec. 7, 2011 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced that Ashleigh Palmer, President and Chief Executive Officer, will be presenting a corporate overview at the 22nd Annual Oppenheimer Healthcare Conference being held in New York City. Mr. Palmer's live presentation is scheduled to begin at 4:10 p.m. ET on Tuesday, December 13, 2011. A live...